Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

    NEXT STORY
    Single-Dose Radiation Therapy At Time Of Lumpectomy Helps Breast Cancer Patients Overcome Treatment Challenges During Pandemic
    PREV STORY
    Adagene Announces Expansion of Leadership Team to Support Strategic Growth
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global Hand Sanitizer Market was Valued at USD 2.0 billion in 2019 and is Expected to Reach USD 5.5 billion by 2025, Observing a CAGR of 17.0% during 2020–2025: VynZ Research

    author_avatar
    NASDAQ Market News

    OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program

    author_avatar
    NASDAQ Market News

    HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead

    author_avatar
    NASDAQ Market News